Krystal Biotech Inc. (KRYS) shares plummeted 5.27% during intraday trading on Monday, reversing earlier pre-market gains.

The biopharmaceutical company reported first-quarter 2026 earnings that exceeded analyst expectations, with adjusted EPS of $1.83 beating the mean estimate of $1.42 and revenue of $116.36 million surpassing the $112.13 million forecast.

However, the stock's decline may be attributed to concerns highlighted in the earnings report, which noted that the mean earnings estimate of analysts had fallen by about 2.5% over the last three months, with two analysts negatively revising their estimates in the past 30 days.